Acrivon Launches CLIA-Certified Watertown Lab, Targets H1 2026 Operations
Acrivon Therapeutics completed CLIA certification on its wholly owned Watertown lab, which will be fully operational in H1 2026, enabling in-house patient testing and companion diagnostic development. This facility gives Acrivon full control over biomarker identification, co-regulatory approvals and could accelerate precision medicine drug development cost-effectively.
1. CLIA Certification and Operational Timeline
Acrivon’s wholly owned Watertown laboratory has received CLIA certification under Massachusetts regulations and holds a full license to conduct patient testing and develop companion diagnostics. The facility is slated to be fully operational in the first half of 2026, enabling immediate in-house sample processing and data analysis.
2. Strategic and Operational Benefits
Bringing CLIA operations in-house grants Acrivon full control over biomarker identification, companion diagnostic development, and co-regulatory approvals, reducing dependency on external labs. The vertical integration is expected to streamline workflows, decrease development costs and accelerate precision medicine programs by integrating AP3 platform outputs directly into clinical assays.
3. Impact on Drug Pipeline and Partnerships
The new lab will support current assets like the ACR-368 endometrial cancer program and next-generation WEE1/PKMYT1 inhibitor ACR-2316, improving assay turnaround for trial biomarkers. Additionally, Acrivon plans to leverage the facility for business development and partner projects, offering lab services to external collaborators seeking precision oncology diagnostics.